Core Viewpoint - Aibo Medical's stock price has fallen significantly, reaching a five-year low, with a nearly 50% drop from its 2024 peak, reflecting a substantial decline in both stock performance and company earnings [2] Financial Performance - Aibo Medical's revenue for the first three quarters of 2025 was 1.144 billion yuan, a year-on-year increase of only 6.43%, while net profit decreased by 8.64% to 290 million yuan, marking the first decline in net profit since its listing [5] - The third quarter of 2025 saw particularly poor performance, with revenue of 358 million yuan, down 8.17% year-on-year, and net profit of 76.84 million yuan, a sharp decline of 29.85%, reaching a new low for quarterly performance [5] - The decline in performance is attributed to decreased revenue from artificial lenses and contact lenses, as well as increased investment in promoting the company's own brand of contact lenses [5][8] Market Dynamics - The average price of artificial lenses has dropped by approximately 60% since being included in the national high-value consumables procurement list in November 2023, which is expected to further impact the company's overall profitability in 2024 [7] - Artificial lenses contribute over 40% to Aibo Medical's revenue, but the company faces challenges in maintaining growth due to price reductions despite increased sales volume [8] - The overall gross margin has decreased from 84.75% in 2022 to 66.23% in 2024, further declining to 64.8% in the first three quarters of 2025 [8] Competitive Landscape - The high-end market for artificial lenses is dominated by international companies such as Zeiss and Alcon, while foreign brands lead in the contact lens sector, intensifying price competition due to domestic capacity expansion [10] - The OK lens market is also facing competition from domestic companies like Haohai Biological and Opcon Vision [10] Shareholder Activity - Major shareholder Bai Ying has reduced her holdings by 3.8627 million shares, approximately 2% of the total share capital, which has raised concerns among investors [11] - Despite the reduction in shares by financial investors, the core management team maintains a stable shareholding structure, with the chairman controlling over 20% of the shares, indicating confidence in the company's long-term prospects [11][12]

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Views - The medical consumables sector saw a 3.77% increase last week, outperforming the CSI 300 index by 2.1 percentage points, indicating a positive trend in the sector [4][12] - The current PE ratio for the medical consumables sector is 32.6X, with a PB ratio of 2.37X, reflecting a slight increase in valuation metrics [5][18] - Recent favorable policies in the pharmaceutical sector are expected to boost market confidence and support the recovery of the medical consumables industry, particularly high-value consumables affected by national procurement policies [6][24] Summary by Sections Industry Performance - The medical consumables sector reported a 3.77% increase, with the overall medical sector also trending upwards [4][12] - The sector's PE ratio has increased by 1.24 percentage points compared to the previous week, with a one-year range of 28.42X to 41.66X [5][17] Industry Dynamics and Key Announcements - The National Healthcare Security Administration issued guidelines for the adjustment of the 2025 basic medical insurance directory, emphasizing the role of commercial health insurance in the multi-tiered medical security system [20][21] - The adjustment of the medical insurance directory is expected to enhance the market entry of innovative drugs, which is a significant step for commercial health insurance [20][21] Investment Recommendations - The report suggests focusing on two main lines for investment: 1. Opportunities for performance recovery post-collection pressure, particularly in orthopedic consumables [24] 2. Increased penetration of innovative products in high-value consumables, such as electrophysiology and interventional devices [24] - The recommendation to maintain an "Overweight" rating on the medical consumables sector highlights the potential for growth in companies with improving performance metrics and innovative product lines [24]

文章来源：心未来；编辑：Sophia 转载要求：如在文首标明文章来源，可直接转载 心未来 在临床实践中，医生和患者常常面临一个选择：是使用进口耗材还是国产耗材。 不同品牌产品之间的主要差异往往体现在"精细程度"上 。国产外周支架 的一个明显劣势在于缺乏长期使用数据和临床积累，尤其是在产品售后和随访方面，往往只是"走个形式"。 从国家层面来看，政府已经给予了国内企业足够长的时间来发展和成长。 然而，在市场竞争中，不可能永远保护国内企业，它们必须学会独立面对各种 挑战。 # 外企低价领跑全场 相比人工耳蜗，外周血管支架的降价幅度更大一些。外周血管支架的作用机理与心脏支架类似，通过支撑、扩张狭窄或堵塞的外周血管改善血流供应状况，帮 助患者恢复行动能力。在集采之前，外周支架的价格从1万多元到5万元不等。 此次外周血管支架集采中，需求量达25.8万个，18家企业中标 ，包括美国康蒂思、柯惠、雅培、波士顿科学等全球知名外资企业，以及上海美创医疗、归创 通桥等内资企业，其中 外资企业占据主导地位，超过90%的份额 。在三个外周血管支架组别中，康蒂思以2280元的最低价中标，波士顿科学在静脉支架A竞 价单元中给出3080元的 ...